Q4 2025 Lantheus Holdings Inc Earnings Call Transcript
Key Points
- Lantheus Holdings Inc (LNTH) reported a strong fourth quarter with revenue of $406.8 million, marking a 4% increase.
- The acquisition of Neuraceq has strengthened the company's Alzheimer's disease portfolio, with expectations for growth to exceed the overall market in 2026.
- The company is preparing for multiple FDA approvals in 2026, including new formulations and products in the PSMA PET and neuroendocrine PET imaging markets.
- Lantheus Holdings Inc (LNTH) completed the divestiture of its legacy spec business, allowing for a more focused investment in innovative PET radio diagnostics.
- The company has a robust late-stage pipeline, with plans to leverage its PMF network and commercial infrastructure to drive revenue growth in 2027 and beyond.
- PYLARIFY revenue declined by 9.7% in the fourth quarter and 6.5% for the full year, indicating challenges in maintaining market share.
- The company anticipates an 8% to 10% decline in PYLARIFY net revenue in 2026 due to potential competitive pricing pressures.
- Operating expenses increased, with research and development costs rising due to planned investments in clinical stage portfolios.
- Free cash flow decreased by $60 million in the fourth quarter compared to the prior year, primarily due to working capital variances.
- The effective tax rate is expected to increase slightly in 2026, impacting overall profitability.
Good morning. Welcome to Lantheus fourth quarter and full year 2025 conference call. (Operator Instructions). This call is being recorded, and a replay will be available in the Investors section of the company's website approximately two hours after the completion of the call, and we will be archived for at least 30 days.
I'll now turn the call over to Mark Kinarney, Vice President of Investor Relations. Mark?
Thank you. Good morning. With me today are Mary Anne Heino, our CEO and Executive Chairperson, Amanda Morgan, our Chief Commercial Officer and Bob Marshall, our CFO. We will begin with prepared remarks and then take your questions. This morning, we issued a press release which was furnished to the SEC under Form 8-K reporting our fourth quarter and full year 2025 results.
The release and today's slide presentation are available on the Investors section of our website. Any comments could include forward-looking statements. Actual results may differ
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
